Brief: Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%
BRIEF-Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42% Oct 23 (Reuters) - Merck & Co Inc MRK.N:
MERCK & CO INC: INTISMERAN PLUS KEYTRUDA SIGNIFICANTLY REDUCED THE RISK OF RECURRENCE OR DEATH BY 42% COMPARED TO KEYTRUDA ALONE
MERCK & CO: SAFETY PROFILE OF INTISMERAN PLUS KEYTRUDA WAS GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF COMBINATION
MERCK: INTISMERAN PLUS KEYTRUDA REDUCED RISK OF RECURRENCE OR DEATH BY 58% COMPARED TO KEYTRUDA ALONE
MERCK & CO: IN PHASE 3 INTERPATH-001 TRIAL NO NEW SAFETY SIGNALS WERE OBSERVED
MERCK: OVERALL SURVIVAL DATA ARE NOT YET MATURE, BUT FAVORABLE TREND IN OS WITH INTISMERAN PLUS KEYTRUDA HAS BEEN OBSERVED
MERCK: INTISMERAN PLUS KEYTRUDA SIGNIFICANTLY REDUCED RISK OF DISTANT METASTASIS OR DEATH BY 38% VERSUS KEYTRUDA ALONE
MERCK: INTISMERAN PLUS KEYTRUDA REDUCED RECURRENCE/DEATH RISK BY 58%, REDUCED RISK OF DISTANT METASTASIS/DEATH BY HALF AT 6 MONTHS VERSUS KEYTRUDA ALONE
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moderna
See all newsMerck/Moderna cancer vaccine cuts risk of melanoma death or recurrence by over 40% (updated)
Brief: Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%
NASDAQ RESUMED AT 12:39 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:34 PM